Alnylam Pharmaceuticals, Inc. (ALNY)
365.33
+9.80
(+2.76%)
USD |
NASDAQ |
Jan 21, 16:00
368.00
+2.67
(+0.73%)
After-Hours: 17:47
Alnylam Pharmaceuticals Free Cash Flow: 221.36M for Sept. 30, 2025
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Insmed, Inc. | -906.14M |
| Pfizer Inc. | 10.38B |
| Biogen, Inc. | 2.262B |
| Bristol Myers Squibb Co. | 15.30B |
| Vertex Pharmaceuticals, Inc. | 3.337B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 325.11M |
| Cash from Investing (Quarterly) | 501.11M |
| Cash from Financing (Quarterly) | -448.35M |
| Free Cash Flow Per Share (Quarterly) | 2.279 |
| Free Cash Flow to Equity (Quarterly) | 279.39M |
| Free Cash Flow to Firm (Quarterly) | 359.62M |
| Free Cash Flow Yield | 0.46% |